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Introduction
Micronutrient deficiencies are common among women in low-income and middle-income countries mainly due to inadequate dietary intake and limited diversity of fruits, vegetables, animal protein, and fortified foods. 1 The burden and severity of micronutrient deficiencies are exacerbated during pregnancy because of increased demands of both the mother and the growing fetus. 2 
It is
Modifiers of the effect of maternal multiple micronutrient supplementation on stillbirth, birth outcomes, and infant mortality: a meta-analysis of individual patient data from 17 randomised trials in low-income and middle-income countries well established that iron-deficiency anaemia in pregnancy can lead to decreased birthweight, and insufficient folate concentrations in the periconceptional period increases the risk of neural tube defects and other adverse outcomes. [3] [4] [5] Deficiencies in other micronutrients including vitamins A, B-complex, D, E, zinc, calcium, copper, magnesium, selenium, and iodine are also prevalent in low-income and middle-income countries and can lead to poor pregnancy, fetal growth, and child health outcomes. 3, [6] [7] [8] As such, maternal multiple micronutrient supplementation including iron-folic acid is a potential intervention to improve maternal and child health as compared with iron-folic acid supplementation alone.
The 2017 Cochrane Systematic Review and metaanalysis that assessed the effect of maternal multiple micronutrient supplements in pregnancy on infant mortality identified 19 randomised controlled trials and pooled data from 17 of these studies. 6 Provision of multiple micronutrient supplements in combination with iron-folic acid during pregnancy reduced the risk of low birthweight (<2500 g; relative risk [RR] 0·88, 95% CI 0·85-0·91) and small-for-gestational-age births (0·92, 0·86-0·98), but had no significant effect on perinatal (1·01, 0·91-1·13) and neonatal mortality (1·06, 0·92-1·22) as compared with iron-folic acid supplementation alone. 6 There was moderate heterogeneity, as measured by I², of the effect of multiple micronutrient supplements on some birth outcomes across published trials but substantial heterogeneity for perinatal mortality. A previously published pooled analysis of 12 multiple micronutrient supplements trials also indicated the effect of multiple micronutrient supplements on birthweight may be greater in pregnant women with higher BMI. 9 In 2016, WHO reviewed their antenatal care recommendations and acknowledged that policy makers in populations with a high prevalence of nutritional deficiencies might wish to provide multiple micronutrient supplements containing iron and folic acid. However, WHO did not universally recommend multiple micronutrient supplements, noting that there was evidence of benefit but also some evidence of harm. 10 The existing data also precluded definitive conclusions if any subgroups experience greater benefits or harm due to multiple micronutrient supplements.
In this study we aimed to elucidate individual-level effect modifiers that might alter the impact of maternal multiple micronutrient supplements on stillbirth, birth outcomes, and infant mortality. We aimed to identify subgroups of pregnant women and infants who might experience greater benefit or harm from multiple micronutrient supplements and explore the sources of the heterogeneity across randomised trials.
Methods
In this two-stage meta-analysis of individual patient data, we identified potential studies for inclusion
Research in context
Evidence before this study Micronutrient deficiencies are common in pregnant women in low-income and middle-income countries. However, debate persists regarding the current WHO recommendation to provide pregnant women with iron-folic acid supplementation alone, rather than multiple micronutrient supplements containing other essential micronutrients in addition to iron-folic acid during routine antenatal care. In the past two decades, more than 20 randomised trials have examined the effect of multiple micronutrient supplements during pregnancy, compared with iron-folic acid alone, on maternal and child health outcomes. The 2017 Cochrane review and meta-analysis established that provision of daily oral multiple micronutrient supplements reduced the risk of low birthweight (<2500 g) and small-for-gestational-age births, but had no overall effect on perinatal and neonatal mortality as compared with iron-folic acid alone.
The recently updated 2016 WHO antenatal care recommendations acknowledged that policy makers in populations with a high prevalence of maternal nutritional deficiencies might wish to provide multiple micronutrient supplements. However, WHO does not universally recommend multiple micronutrient supplements, noting: "There is some evidence of additional benefit of multiple micronutrient supplements containing 13-15 different micronutrients (including iron and folic acid) over iron and folic acid supplements alone, but there is also some evidence of risk, and some important gaps in the evidence".
Added value of this study
This study uses the most detailed approach to analysing existing trial data on multiple micronutrient supplements. Previous meta-analyses identified overall benefits of multiple micronutrient supplements in terms of birth size, but our findings show that specific subgroups experience mortality benefits, notably female neonates. Women with indicators of malnutrition during pregnancy who took multiple micronutrient supplements also had greater reductions in low birthweight, preterm, and small-for-gestational-age births. We found no evidence that multiple micronutrient supplements significantly increased the risk of stillbirth or neonatal, 6-month, or infant mortality, neither overall or in any of the 26 examined subgroups.
Implications of the available evidence
This novel analysis identified subgroups of mothers and infants that might benefit the most from multiple micronutrient supplements. This new evidence suggests that WHO might wish to re-evaluate the balance of benefits and harms of universal multiple micronutrient supplementation in their antenatal care recommendations. through a review of recent meta-analyses. 6, 11, 12 We then updated this list of potential studies using the search strategy employed by the 2015 Cochrane Review to identify randomised controlled trials published up to July 20, 2015. 6 We also reviewed the references of included trials and systematic reviews; there were no language restrictions.
Eligible studies were randomised controlled trials of multiple micronutrient supplements for pregnant women, containing at least three micronutrients; were done in low-income and middle-income countries as defined by the World Bank; included a control group that had received iron and folic acid supplements as part of the trial or as standard of care; whose authors presented data on birth outcomes, stillbirth, or infant mortality; and whose authors agreed to participate in this new individual patient data study. We excluded trials or trial groups that used lipid-based micronutrient supplements and micronutrient-fortified powders as these provided additional calories and nutrients that might have independent effects on outcomes of interest.
All outcomes, subgroups, and statistical methods were defined a priori. Outcomes of interest included: stillbirth, early neonatal (≤7 days age), neonatal (≤28 days age), 6-month (≤180 days age), and infant (≤365 days age) mortality. Birth outcomes included: birthweight, very low birthweight (<2000 g), low birthweight (<2500 g), early preterm (<34 weeks gestation), preterm (<37 weeks gestation), small-for-gestational-age (<10th percentile of weight-for-gestational-age and sex as defined by Oken 13 and Intergrowth 14 standards), and large-for-gestationalage (>90th percentile as defined by Oken 13 and Intergrowth 14 standards). Births that occurred before 33 weeks or after week 43 were excluded from Intergrowth 14 analyses because small-for-gestational-age and large-for-gestational-age cutoffs were not defined for these gestational ages at the time of analysis.
We assessed the effect of multiple micronutrient supplements on all outcomes within the following subgroups selected based on biological plausibility and inclusion in previous meta-analyses: gestational age at randomisation (trimesters and <20 weeks vs ≥20 weeks), parity (1 child vs ≥2 children), maternal age (<18 years vs ≥18 years and <20 years vs ≥20 years), maternal underweight at randomisation (BMI <18·5 kg/m² vs ≥18·5 kg/m²), maternal anaemia at randomisation (<110 g/L vs ≥110 g/L), maternal stature (<150 cm vs ≥150 cm), maternal education (none vs ≥1 year), infant sex (male vs female), and adherence to trial regimen (≥95% vs <95%). We examined the effect of multiple micronutrient supplements on stillbirth and mortality outcomes by the presence of a skilled birth attendant at delivery (yes vs no).
We contacted principal investigators of each study and invited them to participate in this study. Eight trials provided individual-level data to the Harvard T.H. Chan investigators (ERS and CRS) and nine independently conducted the subgroup analyses in accordance with the study protocol and using the same statistical analysis code. We calculated non-parametric relative risk or mean difference estimates and corresponding 95% CIs for individually randomised trials. We calculated estimates and 95% CIs for cluster randomised trials using methods consistent with the primary published paper.
We pooled study-specific relative risk and mean difference estimates using fixed effects models using STATA version 14 METAN command. We excluded trials which did not contribute at least one subject to all strata within a subgroup analysis. Heterogeneity within strata was quantified using the I² test statistic and corresponding p value, while heterogeneity between subgroups was assessed with the χ² test for heterogeneity. We qualitatively assessed study quality using the Child Health Epidemiology Reference Group standards. 15 As a sensitivity analysis for individual subgroup effects, we generated pooled subgroup estimates using randomeffects models; we also examined overall and subgroup effects separately for trials using the same dose of iron in the multiple micronutrient supplements and comparison group and again for the trials using a lower dose iron in the multiple micronutrient supplements group than the comparison group. In addition, we did an influence analysis for significant results whereby we presented pooled estimates omitting each study, one at a time (appendix pp 218-220). 16 To assess publication bias and small study effects we visually inspected funnel-plots (appendix pp 221-224). All individual trials were approved by their respective ethics committees. The pooling study protocol was approved by the Harvard T. H. Chan School of Public Health IRB .
Role of the funding source
There was no funding source for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
We identified 19 randomised controlled trials that met our inclusion criteria, 17 of which were included in this meta-analysis. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Two were not included; one study declined to participate and one could not locate the primary data. 34, 35 Table 1 provides a summary of trials included in the meta-analysis. The trials included 112 953 pregnant women and study-specific sample size ranged from 200 22 to 44 567, 31 with two studies contributing more than two-thirds of total participants. 26, 31 Eight trials used the United Nations multiple micronutrient preparation (UNIMMAP; multiple micronutrient supplements formulations in appendix p 1). 20, 21, 23, [26] [27] [28] [29] [30] All trials used multiple micronutrient supplements preparations that included at least eight micronutrients in addition to iron-folic acid. The See Online for appendix prevalence of effect modifiers and cumulative incidence of study outcomes by trial are presented in the appendix (pp 3, 4). All trials were graded low or moderate risk of bias (appendix p 2). Funnel plots did not provide clear evidence of publication bias or small study effects (appendix pp 221-224). Figure 1 presents subgroup-specific pooled effect sizes for the following outcomes: stillbirth, neonatal mortality, infant mortality, low birthweight, preterm, and small-forgestational-age births as per the Oken standard. Forest plots for all subgroup meta-analyses are presented in the appendix (pp 5-205). Table 2 presents the effect of maternal multiple micronutrient supplements on stillbirth, neonatal mortality, mortality to 6 months, and infant mortality stratified by potential effect modifiers. We did not identify any factors that significantly modified the effect of multiple micronutrient supplements on stillbirth. In meta-analyses including all livebirths, there was no overall effect of multiple micronutrient supplements on mortality at any timepoint; however, there were several subgroups for which multiple micronutrient supplements provided significant survival benefits. We found sex modified the effect of multiple micronutrient supplements on survival in the early neonatal, neonatal, and infant periods (p values for heterogeneity: 0·047, 0·007, 0·04; table 2; appendix p 23). Multiple micronutrient supplements significantly reduced the risk of neonatal mortality by 15% among females (95% CI 4-25) with a similar magnitude of reduction for early neonatal, 6 months, and infant mortality. Significant mortality benefits of multiple micronutrient supplements for females were also found at all timepoints in random effects sensitivity analyses (appendix p 206). Multiple micronutrient supplements provided significantly greater 6-month mortality reduction among anaemic pregnant women as compared with non-anaemic pregnant women (RR 0·71, 95% CI 0·60-0·86 vs 0·93, 0·78-1·11; p value for heterogeneity 0·04). Maternal adherence to the intervention also modified the effect of multiple micronutrient supplements on infant mortality, with survival benefits for infants born to women with higher than 95% adherence to the supplements ( Gestational age at multiple micronutrient supplements initiation modified the effect of supplementation. Women initiating multiple micronutrient supplements before 20 weeks gestation had greater reductions in the risk of preterm birth (RR 0·89, 95% CI 0·85-0·93; p value for heterogeneity 0·03; table 3). However, multiple micronutrient supplements provided greater reductions in the risk of small-for-gestational-age birth in women initiating supplementation after 20 weeks (RR 0·91, 95% CI 0·86-0·96; p value heterogeneity 0·004; table 3). Multiple micronutrient supplements initiation before or after 20 weeks gestation conferred similar benefits in reducing the risk of low birthweight (table 3) .
As a sensitivity analysis, we stratified studies by whether or not they used the same dose of iron in the multiple micronutrient supplements and iron-folic acid groups. The appendix provides overall estimates (appendix p 208) and subgroup estimates (appendix pp 209-217) of the effect of multiple micronutrient supplements for trials using the same dose of iron in the multiple micronutrient supplements and iron-folic acid alone groups versus trials using a lower dose iron in the multiple micronutrient supplements group than the iron-folic acid alone group (all used ≤30 mg iron for multiple micronutrient supplements and 60 mg iron for iron-folic acid alone). Among trials using the same dose of iron in both groups, the benefits of multiple micronutrient supplements were consistent with the primary analysis. By contrast, some subgroups given multiple micronutrient supplements with low dose iron (≤30 mg) had higher stillbirth and neonatal mortality than iron-folic acid alone with 60 mg iron. Specifically, multiple micronutrient supplements containing a lower dose of iron than the iron-folic acid comparison group were associated with an increased stillbirth rate among first pregnancies, early neonatal mortality in women who initiated supplementation before 20 weeks gestation, early neonatal and neonatal mortality in women with <95% adherence, and early neonatal mortality for multigravidae.
Discussion
Our findings show that pregnant women who take antenatal multiple micronutrient supplements including iron-folic acid have a lower risk of having a baby with low birthweight, a preterm birth, or having a small-forgestational-age baby. Furthermore, we identified several factors that modified the effect of multiple micronutrient supplements on infant survival and birth outcomes.
The effect of multiple micronutrient supplements on survival was modified by infant sex. Multiple micronutrient supplements consistently reduced mortality by about 15% in females during the first year of life, but we did not record significant benefits in males. The biological mechanisms leading to these sex differences are not clear. West and colleagues 31 and Lee and colleagues 36 have previously proposed that sex differences in the mortality effect of multiple micronutrient supplements could be explained by differences in birth size by sex. Males have greater length, head circumference, and birthweight on average than females, and increased birth size due to multiple micronutrient supplements might lead to greater birth complications in males. 37 However, we noted no sex differences in the effect of multiple micronutrient supplements on stillbirth, which suggests that effect modification by sex might operate through other mechanisms or vary with the population context. The burden of infections and leading causes of mortality have been shown to vary by infant sex; 38, 39 additional information about the causes and timing of deaths within trials might help clarify why multiple micronutrient supplements seem to be more beneficial for female infants. Nevertheless, we do not recommend programmes considering implementation of multiple micronutrient supplements target only pregnant women carrying female fetuses as both male and female neonates experience birthweight benefits and small positive survival benefits are possible in males.
Multiple micronutrient supplements had a bigger effect on birth outcomes in women with poor nutritional status, as indicated by anaemia or low BMI, at the start of supplementation, as initially reported in the SUMMIT study. 26 Anaemic women had greater reductions in the risk of low birthweight, small-for-gestational-age birth, and mortality to 6 months than non-anaemic pregnant women. The effect of multiple micronutrient supplements on preterm birth was also greater for pregnant women who had a BMI of lower than 18·5 kg/m² at the start of supplementation. These findings suggest that iron-folic acid alone is likely an insufficient intervention for anaemic pregnant women and justifies continued focus on anaemia and low BMI as key effect modifiers for nutrition interventions in pregnancy. A recent multiple micronutrient supplements trial 34 done in China among non-anaemic and mildly anaemic women (not included in our meta-analysis) found no effect of multiple micronutrient supplements on perinatal mortality and a non-significant 10% reduction in low birthweight. These findings are consistent with our non-anaemic subgroup results, which showed no effect of multiple micronutrient supplements on early neonatal, neonatal, or infant mortality and an 8% reduction in low birthweight.
Due to the clustering of protein-energy and micronutrient deficiencies, we cannot directly examine whether improvement in maternal haemoglobin status mediated a greater effect of multiple micronutrient supplements on low birthweight in anaemic women. Anaemia might be a proxy for deficiencies of micronutrients included in multiple micronutrient supplements, as well as numerous other factors including maternal infection. 40, 41 Findings of a previous metaanalysis showed that multiple micronutrient supplements (which included iron) had a similar effect on haemoglobin and anaemia than iron alone or iron with folic acid. 42 Notably, some trials included in our meta-analysis and the anaemia meta-analysis used higher dose iron in the control group than the multiple micronutrient supplements arm, which might have attenuated the haemoglobin, mortality, and birth outcome effects of multiple micronutrient supplements, particularly in anaemic pregnant women. 20, 21, [27] [28] [29] 32, 33, 35, 42 Despite this, we still find a larger effect of multiple micronutrient supplements among anaemic than for non-anaemic pregnant women. There are several haemoglobin independent pathways by which multiple micronutrient supplements might improve birth outcomes, 5 including reductions in maternal and fetal inflammation, 43 improvements in oxidative metabolism and placental function, 44, 45 and altered maternal endocrine effects. 46 Although the biological mechanisms through which multiple micronutrient supplements provides benefits are unclear, our meta-analysis indicates that the populationlevel benefits for birth outcomes are likely to be greater in settings with high rates of maternal nutritional deficiencies. It is also important to note that in the MINIMat trial women who received both early food supplementation and multiple micronutrient supplements had the lowest rate of infant mortality; 30 combined macronutrient and micronutrient interventions might produce even greater effects in settings with high rates of maternal malnutrition.
We did not identify any subgroup that experienced significantly elevated risk of stillbirth or mortality at any timepoint in the primary analysis. Multiple micronutrient supplements trial reports have raised concerns that increased birth size due to multiple micronutrient supplements may increase the risk of cephalopelvic disproportion and neonatal asphyxia, particularly among women of small stature. 17, 31 We found that multiple micronutrient supplements indeed increased the risk of large-for-gestational-age births (as defined by the Intergrowth standard 14 ), which could hypothetically increase the risk of maternal-fetal disproportion and related birth complications. However, we found no indication that mothers who took multiple micronutrient supplements and whose height was less than 150 cm had increased risk of stillbirth or mortality at any timepoint. As such, alternative interpretations or mechanisms to explain no overall effect of multiple micronutrient supplements on mortality should be explored.
We also provide evidence that iron dosage influences the observed effect of multiple micronutrient supplements on stillbirth and mortality. Specifically, the sensitivity analyses revealed benefits and no significant harmful effects overall or in any subgroup among trials that used the same dose of iron in the multiple micronutrient supplements and iron-folic acid alone arms. By contrast, the sensitivity analyses also found that multiple micronutrient supplements with low dose iron (<30 mg) results in a higher observed stillbirth and mortality in some subgroups when compared to ironfolic acid alone with 60 mg iron. The most recent Cochrane Review found similar effect modification by iron dose on perinatal mortality. 6 Furthermore, the WHO antenatal care guidelines noted the potential for harmful effects of multiple micronutrient supplements on neonatal mortality among a subgroup analysis in which 5 out of 6 trials used low dose iron (≤30 mg) in the multiple micronutrient supplements group and 60 mg iron in the iron-folic acid alone group. 10 Taken together with previous analyses, our data suggest that both iron and multiple micronutrients have beneficial effects and that multiple micronutrients together with iron-folic acid provide even greater benefits than iron-folic acid alone. Accordingly, countries and programmes considering implementation of multiple micronutrient supplements should use a formulation with an iron dose similar to what they currently use; for example, multiple micronutrient supplements that contains 60 mg iron should be considered in settings where 60 mg iron-folic acid is currently implemented.
Notwithstanding the large sample size and consistency of our findings, there are several limitations to our metaanalysis. First, because of the number of subgroup analyses we did, there is an increased risk of type 1 errors inherent to the number of heterogeneity tests presented. However, our findings as a whole exceed those that would be expected by chance; 13 of 70 tests for heterogeneity for mortality outcomes were significant (probability of occurring by chance alone <0·01%). There is also low probability of finding 26 of 146 subgroups had significant survival benefits (<0·01%) and that no subgroups had increased mortality risk (2·5%) if we construct a hypothesis assuming there was no true effect of multiple micronutrient supplements on mortality in any subgroup. Second, as previously discussed, some trials used a higher dose of iron in the control group as compared with the multiple micronutrient supplements group, and our sensitivity analysis suggests that inclusion of these trials resulted in attenuation of the effect of multiple micronutrient supplementation because the iron-folic acid alone group participants might have experienced benefits from additional iron. 20, 21, [27] [28] [29] 32, 33 Third, the JiVitA-3 31 and SUMMIT 26 trials are weighted heavily in many of the subgroup strata because of their large sample sizes and high event rates. Our sensitivity analyses show that sex differences in the effect of multiple micronutrient supplements on neonatal mortality are robust to excluding either of these studies (appendix pp 218-220). However, the stronger benefit of multiple micronutrient supplements on 6-month mortality in infants born to anaemic women is driven by the SUMMIT study, 26 and the stronger benefit of multiple micronutrient supplements on preterm birth among infants born to underweight women and infant mortality among male infants, are driven by JiVitA-3 31 (appendix pp 218-220). Fourth, we were unable to examine HIV as a potential effect modifier since only two trials included both HIVinfected and HIV-uninfected women. Nevertheless, there was no indication that the effect of multiple micronutrient supplements varied by maternal HIV status in these studies. 19, 32 Finally, although our analysis identified several maternal and child factors that alter the effect of multiple micronutrient supplements on mortality and birth outcomes, we can provide only limited insight into the biological mechanisms through which multiple micronutrient supplements may operate. As poor socioeconomic status, significant barriers to health services, and nutritional deficiencies often coexist, the effect modifiers we examined in this analysis (eg, skilled birth attendants, maternal underweight, and maternal anaemia) have overlap as indicators of underlying adversity. Even so, the factors identified in this paper suggest subgroups that might experience the greatest benefits from multiple micronutrient supplements, irrespective of the mechanisms through which multiple micronutrient supplements operates.
Our findings established that multiple micronutrient supplements reduced mortality in female neonates, and although multiple micronutrient supplements increased birthweight and reduced preterm among all infants, the greatest effects were for those born to pregnant women with nutritional deficiency as indicated by anaemia or low BMI. Based on the included data and methods of this study, we also found none of the 26 subgroups, or the population overall, showed multiple micronutrient supplements significantly increased the risk of stillbirth or neonatal, six-month, or infant mortality. A systematic review 47 that assessed the long-term health effects noted no significant evidence that multiple micronutrient supplements improved child growth, body composition, blood pressure, respiratory, or cognitive outcomes as compared with iron folic-acid alone. However, a recently published long-term follow-up study 48 of SUMMIT found that multiple micronutrient supplements significantly improved procedural memory and produced better scores on 18 of 21 cognitive tests among Indonesian children aged 9-12 years.
This new evidence suggests that WHO should consider re-evaluating the balance of benefits and harms of universal multiple micronutrient supplements in their antenatal care recommendations. Programmes and lowincome and middle-income countries considering implementation of multiple micronutrient supplements have the opportunity to simultaneously expand coverage of early antenatal care attendance and multiple micronutrient supplements including iron-folic acid, while also improving the quality of antenatal care counselling and services to produce population-level infant health benefits, which might be greater than any of these strategies in isolation. Packaging multiple micronutrient supplements with effective antenatal care interventions for coordinated delivery is consistent with the Sustainable Development Goals, which emphasise the identification of intervention synergies that have the potential for rapid impact. 49 Contributors ERS, CRS, AHS, and WWF designed the study (project conception, development of overall research plan, and study oversight). All authors contributed input and reviewed the study protocol and assisted or completed statistical analyses for their respective trials. ERS, LS-FW, and CRS developed statistical programme code for trial-specific analyses. ERS and CRS pooled the data and did the meta-analyses. ERS and CRS drafted the initial paper and have primary responsibility for final content. All authors reviewed and contributed to the final manuscript.
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